Eribulin and Radiation for Liposarcoma Treatment
Author Information
Author(s): Davis Lara, Zhu Limin, Mayo Skye C., Latour Emile, Park Byung, Huang Wei, Moloney Brendan, Davis Jessica L., Wakeman Kristina, Sheppard Brett, Billingsley Kevin G., Vetto John, Valenzuela Cristian D., Eil Robert L., Rocha Flavio, Hung Arthur, Ryan Christopher W.
Primary Institution: Oregon Health & Science University
Hypothesis
Can preoperative eribulin combined with radiation improve outcomes for patients with resectable retroperitoneal liposarcoma?
Conclusion
The combination of preoperative eribulin and radiation is safe and shows promise for treating resectable retroperitoneal liposarcoma.
Supporting Evidence
- Four patients treated at the starting dose level had no dose-limiting toxicities.
- The recommended phase 2 dose was established as eribulin 1.4 mg/m2 and IMRT 50.4 Gy.
- Median recurrence-free survival was 30.4 months.
- Median overall survival was 54.1 months.
- 81.8% of patients achieved R0 resection.
Takeaway
This study tested a new treatment for a type of cancer called liposarcoma, and it found that combining two therapies is safe and might help patients live longer without their cancer coming back.
Methodology
Patients received preoperative intensity-modulated radiation therapy with escalating doses of eribulin in an open-label dose-finding study.
Potential Biases
Potential bias due to the open-label design and small sample size.
Limitations
The study had a small sample size and limited number of events, which may affect the reliability of the results.
Participant Demographics
The study included 15 patients, with a median age of 63.9 years, and 46.7% were female.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 12.0-NR for recurrence-free survival; 95% CI 9.5-NR for overall survival.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website